GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to headline-grabbing agents of a global weight-loss revolution. But the science, strategy, and scale behind these therapies are far more complex than the public narrative suggests.
This exclusive eBook, The GLP-1 Gold Rush, offers a deep dive into the multifaceted world of GLP-1s, from cutting-edge R&D to manufacturing scale-up, formulation innovation, and the next generation of therapeutic targets.
Highlights include:
The race to develop long-acting, oral, and inhalable formulations
Insights into AI-driven peptide design and transdermal delivery potential
Analytical hurdles in characterizing complex synthetic peptides
Perspectives from Novo Nordisk, Waters, Charles River, DFE Pharma, and more
A look at novel indications—from cardiovascular protection to alcohol use disorder and cognitive decline
Whether you’re driving GLP-1 innovation, optimizing delivery platforms, or evaluating market opportunities, this eBook delivers timely intelligence to inform your strategy. With the anti-obesity market scaling rapidly – and next-gen GLP-1s poised to extend far beyond weight loss – the time to engage is now.
Download this free eBook to stay ahead of the curve in one of pharma’s most dynamic and disruptive domains.
Download the eBookNewsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
